Physician profile
Allison Dunaway
NPI 1154088805
$10,292.27
in general payments reported to CMS, 2019-2025
34 companies · $2,853 in 2025
The $2,853 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $2,520 · 2023: $2,313 · 2024: $2,346 · 2025: $2,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,512.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,773.56 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,025.87 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $968.79 | 2022-2025 | |
| Amgen INC. | $717.91 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $668.70 | 2022-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $666.47 | 2022-2025 | Verquvo, Winrevair |
| Novo Nordisk INC | $498.67 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $384.57 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Medtronic, INC. | $365.41 | 2022-2024 | Aurora Ev-Icd Mri Surescan, Reveal Linq |
| Alnylam Pharmaceuticals INC. | $275.91 | 2022-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $269.02 | 2024-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $244.46 | 2021-2025 | Barostim Neo System |
| Boston Scientific Corporation | $213.81 | 2023-2024 | |
| Daxor Corporation | $189.82 | 2022-2024 | Bva-100 |
| Janssen Pharmaceuticals, INC | $186.75 | 2022-2024 | Xarelto |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $186.67 | 2023 | Tyvaso |
| Pfizer INC. | $183.08 | 2022-2025 | |
| Esperion Therapeutics, INC. | $162.59 | 2022-2024 | Nexletol |
| Zoll Respicardia, INC. | $142.84 | 2022 | |
| Edwards Lifesciences Corporation | $132.53 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kaneka Medical America LLC | $123.01 | 2025 | Apheresis Machine |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.74 | 2022-2025 | Lifevest |
| Bridgebio Pharma, INC. | $114.13 | 2025 | Attruby |
| Amarin Pharma, INC. | $112.86 | 2022 | |
| Abiomed | $109.70 | 2023 | Impella |
| Impulse Dynamics (USA) INC. | $97.80 | 2022-2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $67.57 | 2023 | Inpefa |
| Daiichi Sankyo INC. | $66.91 | 2023-2025 | Injectafer |
| Philips North America LLC | $59.07 | 2024 | (Cm9) Amb Mon & Diag Und |
| Vivaquant INC, Dba Rhythm Express | $56.97 | 2025 | Rhythm Express |
| Inspire Medical Systems, INC. | $37.23 | 2023-2025 | Inspire |
| Scpharmaceuticals INC. | $36.99 | 2023-2025 | |
| Lilly USA, LLC | $19.86 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $18.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Dunaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.